Clinical Trials Logo
  1. Home
  2. Chemotherapeutic Toxicity
  3. NCT04277650

System for High-Intensity Evaluation During Radiotherapy — SHIELD-RT  

Chemotherapeutic Toxicity Clinical Trial

Official title:
System for High Intensity EvaLuation During Radiation Therapy (SHIELD-RT): A Prospective Randomized Study of Machine Learning-directed Clinical Evaluations During Outpatient Cancer Radiation and Chemoradiation

Clinical Trial Summary

This quality improvement project will evaluate the implementation of a previously described intervention (twice per week on-treatment clinical evaluations) in a feasible fashion using a previously described machine learning algorithm identifying patients identified at high risk for an emergency visit or hospitalization during radiation therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04277650
Study type Interventional
Source Duke University
Contact
Status Completed
Phase N/A
Start date September 7, 2018
Completion date June 30, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05959720 - Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Recruiting NCT06041477 - Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC Phase 3
Recruiting NCT06421610 - OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. Phase 1
Recruiting NCT06012253 - The Effect of Home-Based Walking Program on Peripheral Neuropathy, Fatigue and Quality of Life N/A
Recruiting NCT06197581 - Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer N/A
Not yet recruiting NCT04965532 - Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia N/A
Completed NCT04843410 - Effect of Exercise in the Management of Peripheral Neuropathy N/A
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A
Terminated NCT04607668 - Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): Phase 3
Completed NCT05635929 - Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients. N/A
Recruiting NCT06357871 - Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer
Completed NCT02996201 - Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial N/A
Completed NCT00292526 - Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients Phase 4
Completed NCT04663178 - Foot Bath and Chemotherapy Induced Fatigue N/A
Recruiting NCT03191461 - Myocardial Perfusion and Fibrosis in Cancer Survivors
Recruiting NCT05251922 - Tolerance of Anti-Cancer Therapy in the Elderly
Not yet recruiting NCT06387901 - Investigating Paclitaxel Toxicity in Breast Cancer: The Roles of Physical Activity and Body Composition.
Recruiting NCT05892146 - Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction N/A
Not yet recruiting NCT05921149 - Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer N/A
Recruiting NCT05302336 - AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer Phase 4